The merger combines two of the country's largest power generators as demand for electricity surges. Airline stocks have been doing well recently, and the results suggest that can continue.
AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
The merger combines two of the country's largest power generators as demand for electricity surges. Airline stocks have been doing well recently, and the results suggest that can continue. The ...
AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...
RingCentral (RNG) shares have gained nearly 19% over the past six months, driven by expanding AI initiatives, strong demand ...
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback